ADC company Araris Biotech raises CHF15.2m
New ADC company Araris Biotech has got backing by Pureos Bioventures and co-investors in a CHF15.2m seed round to develop a new class of antibody drug conjugates.
·
Vifor Pharma in US$100m licence deal with Cara Therapeutics
Vifor Pharma and Cara Therapeutics have signed a US license agreement for Korsuva to treat dialysis patients with pruritus.
Atriva Therapeutics gets 24m from EIB
Atriva Therapeutics has secured a 24m loan to push the development of its COVID-19 programme ATR-002, an antiviral, anti-inflammatory MEK inhibitor.
Topas raises 22m in Series B financining
Topas Therapeutics GmbH will use the 22m proceeds from a Series B Financing to advance two pipeline candidates.
Siemens launches COVID-19 antigen lateral flow test
Siemens Healthineers has launched its Clinitest Rapid COVID-19 Antigen Test in Europe, which can identify persons infected with SARS-CoV-2 in 15 minutes.
Priothera closes 30m Series A financing
Priothera Ltd. wants to use 30m from a Series A financing to develop a licenced therapy for acute myeloid leukemia (AML).
COVID-19 jab: EU signs contract with JNJ
Johnson & Johnson (JNJ) has inked a contract with the European Commission to supply 200 million doses of its COVID-19 vaccine to the European Union.
Santhera ends development of idebenone
Swiss Santhera Pharmaceuticals has discontinued Phase III development of its DMD drug and will restructure its pipeline.
Nobel Prize in Physiology for HCV pioneers
The Nobel Prize in Physiology or Medicine goes to Harvey J. Alter, Michael Houghton and Charles M. Ric
Swiss Sophia Genetics to expand globally
Swiss Sophia Genetics has raised $110m, to expand marketing of its AI-driven cancer and genetic disease decision support platform globally.